Navigation Links
US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
Date:8/19/2010

are proud of the team effort within the US Oncology Research network that has allowed independent community-based physicians to participate in the development of new treatments for cancer."

"There are so many lives lost to cancer," said Dr. Kolibaba. "US Oncology Research and its physician participants understand that research leads to cancer cures, that new therapies extend survival, and that carefully conducted clinical trials are the only way that progress is achieved. There is no better way to help patients than to offer new treatments. Through participation in clinical trials, physicians can do both, treating cancer patients with the best possible care and moving the field forward."

US Oncology Research is physician-led and physician-driven with a successful history of clinical depth and expertise.  

  • More than 43,000 patients have participated in US Oncology Research trials.  
  • With the approval of Tasigna, US Oncology Research has played a role in the development of 42 cancer therapies approved by the FDA in less than two decades.
  • The US Oncology Research network includes more than 80 practices in 200 locations across the U.S.
  • The network supports 14 sites that offer Phase I trials, including first-in-human trials.
  • At any given time, the network has more than 200 active trials.
  • Leadership at US Oncology Research consists of experts in a wide variety of cancer specialties including Breast Cancer, Developmental Therapeutics, Gastrointestinal Cancer, Hematologic Cancer, Gynecologic Cancer, Genitourinary Cancer, Lung Cancer, Translational Oncology Program, and Radiation Therapy.
  • 57 manuscripts from investigator-initiated studies have been published in peer-reviewed journals.
  • US Oncology Research supports the nation's largest research network specializing in Phase I-IV oncology clinical trials.  Investigator- and sponsor-initiated
    '/>"/>

SOURCE US Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
2. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
3. US Oncology Pharmaceutical Distribution Service Wins National Safety Council Award
4. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
5. OncologySTAT Advisors Name Years Top Developments in Cancer Treatment and Research
6. First Coast Oncology to Offer Next Generation Proton Therapy
7. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
8. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
9. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
10. Varian Medical Systems Introducing OncoView(TM) - an Oncology Specific Image Management and Storage Solution
11. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... "Company"), a diversified life sciences company, today announced that ... authorized shares of common stock of the Company from ... held on July 27, 2015 at the Law Offices ... Meeting").   At the Special Meeting, there were 480,655,929 shares ...
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that it has granted to German life sciences ... development and commercialization of biotechnology (collectively, the "Optionee"), ... oral allogenic tumor vaccine technology (the "Technology"), including ... cancer which is ready to enter a Phase ...
(Date:7/27/2015)... FRANKLIN, Tenn. , July 27, ... provider of health care services and one of ... today announced that its parent company and sole ... agreement with Medical Properties Trust, Inc. ("MPT") (NYSE: ... for $900 million in cash.  The transaction is expected to ...
(Date:7/27/2015)... MONTREAL , July 27, 2015   ... that produces sustainable biological accelerators for farmers, has ... Patent and Trademark Office for its patent application ... that accelerate plant growth and enhance yields on ... patent relates to Inocucor,s live IN-M1 microbial consortium ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3
... the Americas -- The Agreement for Europe Will ... of DNA Extraction Kits -- ZyGEM,s Technology Enables ... Automation and High-Throughput Applications -SOLANA BEACH, Calif., and ... Corp. Ltd. and VWR International Europe bvba today ...
... EMERYVILLE, Calif., March 26 Neurobiological Technologies, Inc. (NTI(R)) ... has hired RBC Capital Markets as its exclusive financial ... to enhance shareholder value, including a potential sale of ... Capital Markets to assist us in efficiently determining if ...
... recent study using state-of-the-art genetic testing shows that an all natural skin ... Sirtuin-1, a key anti-aging gene. Until now only Resveratrol, a substance ... to naturally stimulate Sirtuin-1 in humans. Ambra-Lift™ contains no Resveratrol. ... ...
Cached Biology Technology:ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 2ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 3ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 4Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company 2Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 2Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 3Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 4
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... When investigating cancer cells, researchers discovered numerous peculiarities: ... genes are overactive. Do these characteristics have a relation ... inactivate growth brakes or are they just a whim ... scientists perform what are called loss-of-function analyses. They knock ...
... the University of Hawaii Cancer Center and The Queen,s ... from the National Cancer Institute to develop novel methods ... analysis of gene expression and imaging data of the ... a research scientist at the UH Cancer Center, and ...
... An extreme form of pregnancy-related nausea and vomiting known ... of women each year and can lead to hospitalization and ... the only victims. A joint study by ... children whose mothers suffered from HG while carrying them were ...
Cached Biology News:A question of gene silencing 2Hawaii receives funding for liver cancer research 2Extreme morning sickness could lead to lifelong emotional, behavioral disorders in kids 2
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
... formulated for covering tissue sections and cell preparations ... alcohol insoluble end products. UltraMount Plus ... Red or AEC that require an aqueous mounting ... DAB. No heating is required prior to use. ...
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
Biology Products: